Tagrisso, a medication developed by AstraZeneca, is used to treat certain types of non-small cell lung cancer (NSCLC) [1]. The price of Tagrisso can vary depending on factors such as dosage, insurance coverage, and geographic location [2].
How much does Tagrisso cost without insurance?
Without insurance, the list price for a 30-day supply of Tagrisso (osiertinib) can range significantly, often in the tens of thousands of dollars. For example, a 30-day supply of 40mg tablets has been priced around $12,000 to $15,000, while the 80mg tablets could be in a similar range or slightly higher, approximately $12,000 to $16,000 [2]. These figures are subject to change and can be influenced by pharmacy pricing and manufacturer programs [2].
What assistance programs are available for Tagrisso?
AstraZeneca offers patient assistance programs that may help reduce the out-of-pocket costs for eligible individuals [3]. These programs can include co-pay assistance for commercially insured patients and free medication for uninsured or underinsured patients who meet certain financial criteria [3]. Information about these programs is typically available through the manufacturer's website or by speaking with a healthcare provider or pharmacist [3].
When does Tagrisso's patent expire?
The patent landscape for Tagrisso is complex, with multiple patents covering different aspects of the drug, including its composition of matter and methods of use [4]. Information from DrugPatentWatch.com indicates that while some early patents may have expired or are nearing expiration, others that provide extended market exclusivity could remain in effect for several years [4]. Understanding the exact patent expiry dates is crucial for predicting when generic versions might become available [4].
What are the approved uses for Tagrisso?
Tagrisso (osimertinib) is primarily approved for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC whose disease has progressed on or after prior EGFR tyrosine kinase inhibitor therapy [1]. It is also approved for adjuvant treatment of patients with NSCLC whose tumors have an EGFR exon 19 deletion or exon 21 (L858R) substitution, after surgical resection [1].